Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
854 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT03215511 | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | completed | Phase 1 | 81 | BayerINDUSTRY | 10 | Oct 30, 2024 | clinicaltrials |
| NCT04435639 | Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema | suspended | N/A | 30 | Institute of Technology, SligoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)(PREMISE) | completed | — | 1,763 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Oct 21, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-4) | terminated | Phase 3 | 117 | GlaxoSmithKlineINDUSTRY | 19 | Oct 9, 2024 | clinicaltrials |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ(IBIS-II DCIS) | completed | Phase 3 | 2,980 | Queen Mary University of LondonOTHER | 14 | Sep 19, 2024 | clinicaltrials |
| NCT00626106 | QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 156 | NantCell, Inc.INDUSTRY | 9 | Sep 19, 2024 | clinicaltrials |
| NCT01607957 | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(RECOURSE) | completed | Phase 3 | 800 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 19, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT05613023 | A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT(PACE-NODES) | recruiting | Phase 3 | 1,128 | Institute of Cancer Research, United KingdomOTHER | 3 | Sep 19, 2024 | clinicaltrials |
| NCT06287294 | An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer | recruiting | — | 120 | Our Lady's Hospice and Care ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588933 | TQ-PAL Development and Validation | recruiting | — | 200 | Prof Andrew DaviesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
| NCT06550063 | HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes(HERA) | unknown | — | 2,188 | St. James's Hospital, IrelandOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT06147479 | Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia(CS-ADL) | completed | N/A | 16 | National University of Ireland, Galway, IrelandOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 3 | 388 | GlycoMimetics IncorporatedINDUSTRY | 9 | Jul 29, 2024 | clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT01660451 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | completed | Phase 2 | 227 | BayerINDUSTRY | 25 | Jul 17, 2024 | clinicaltrials |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-3) | terminated | Phase 3 | 315 | GlaxoSmithKlineINDUSTRY | 26 | Jul 10, 2024 | clinicaltrials |
| NCT02676986 | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer(ARB) | completed | Phase 2 | 221 | Queen Mary University of LondonOTHER | 5 | Jul 5, 2024 | clinicaltrials |
| NCT04654975 | Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)(METABREC) | unknown | — | 10,000 | Universitaire Ziekenhuizen KU LeuvenOTHER | 6 | Jul 3, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT04626349 | International Study to Evaluate Two Programs of Support for Patients With Advanced Cancer and Their Families(DIAdIC) | completed | N/A | 431 | Vrije Universiteit BrusselOTHER | 6 | Jun 12, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | completed | Phase 1 | 333 | Regeneron PharmaceuticalsINDUSTRY | 5 | May 1, 2024 | clinicaltrials |
| NCT05378152 | Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity | completed | N/A | 82 | Royal College of Surgeons, IrelandOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03935763 | Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective(PROMETCO) | unknown | — | 738 | Servier Affaires MédicalesINDUSTRY | 18 | Apr 22, 2024 | clinicaltrials |
| NCT06007001 | Telerehabilitation and Tele-psychological Support in Cancer Patients eCAN JA(eCAN) | unknown | N/A | 354 | SciensanoOTHER_GOV | 10 | Apr 19, 2024 | clinicaltrials |
| NCT05973175 | REFUEL PCOS Study 1(REFUEL-PCOS) | unknown | — | 40 | Royal College of Surgeons, IrelandOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT03377660 | Resection of the Esophagus and Subsequent Weight Loss(REWARD) | terminated | — | 30 | Imperial College LondonOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06327139 | Optimising Patient Experience in Head and Neck Radiotherapy(OPEN) | unknown | Phase 3 | 201 | Irish Research Radiation Oncology GroupNETWORK | 1 | Mar 25, 2024 | clinicaltrials |
| NCT00382070 | Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer | unknown | Phase 3 | 3,966 | NSABP Foundation IncNETWORK | 3 | Mar 22, 2024 | clinicaltrials |
| NCT05305820 | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy(PANO) | unknown | N/A | 36 | Dublin City UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT05458401 | EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan(EUROPA T-DXd) | completed | — | 256 | Daiichi SankyoINDUSTRY | 3 | Mar 15, 2024 | clinicaltrials |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer(STRATEGIC-1) | unknown | Phase 3 | 464 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 3 | Mar 12, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | completed | Phase 2 | 15 | Cancer Trials IrelandNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02013167 | Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 3 | 405 | AmgenINDUSTRY | 21 | Mar 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials